CART‑EGFR‑IL13Rα2 (EGFR/IL13Rα2 bivalent CAR‑T) shows 12.0‑mo mOS with no late safety signals in recurrent GBM

Eighteen patients with recurrent EGFR-amplified GBM received a single intracerebroventricular dose of CART‑EGFR‑IL13Rα2, an autologous bivalent CAR‑T designed to recognize EGFR (806 epitope) and IL13Rα2 (Phase 1, 3+3 dose escalation; data cut-off January 16, 2026; NCT05168423). With median follow-up 18.5 months, median OS was 12.0 months (95% CI 7.4–23.2) and 3/18 patients lived >18 months—numerically above typical post-recurrence medians reported with lomustine±bevacizumab (8.6–9.1 months) and regorafenib (7.4–7.6 months) in largely first-relapse settings, though cross-trial comparisons are confounded by eligibility/line-of-therapy differences. Safety remained consistent with earlier reporting: aside from one prolonged Grade 1 neurotoxicity, there were no prolonged/late-onset/unexpected toxicities, no on-target off-tumor signal, and no secondary cancers; neurologic function (NANO) transiently worsened at day 1 after first infusion (mean +1.9; p=0.09) and returned to baseline by day 4, with no meaningful change at 1 month (+0.41; p=0.998) or 2 months (+0.54; p=0.992), and retreatment at progression (n=7) did not reproduce the day‑1 NANO spike.